Latest News

Price of alirocumab would have to be cut to be cost-effective




(HealthDay)—For patients with a recent acute coronary syndrome receiving a statin, the price of alirocumab would have to be reduced to be cost-effective, according to a study published online Jan. 1 in the Annals of Internal Medicine.

Source link




Related posts

Medical News Today: Through my eyes: Cannabinoid hyperemesis syndrome (CHS)

Newsemia

Medical News Today: What causes a loss of appetite?

Newsemia

Medical News Today: Regular sleep schedule likely benefits metabolic health

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy